Side effects of antiretroviral treatment such as lipoatrophy have been mainly attributed to mitochondrial toxicity of nucleoside reverse transcriptase inhibitors (NRTIs). We assessed whether uridine can abrogate the adverse effects of NRTIs on adipocyte functions.
Methods
3T3-F442A preadipocytes were exposed to stavudine (d4T; 10 μM), zidovudine (ZDV; 1 μM), zalcitabine (ddC; 0.2 μM) or didanosine (ddI; 10 μM) in the absence or presence of uridine 21 days prior to and 7 days after induction of differentiation. Then, lipid accumulation (oil red staining), apoptosis (flow cytometry, PARP-cleavage), mitochondrial mass (Mitotracker) and DNA (mtDNA), cytochrome c oxidase (COX) subunits and mitochondrial membrane potential (JC-1) were quantified.
Results
Whereas ddI had no effects, d4T, ZDV and ddC significantly decreased cellular lipid accumulation (by 32%, 46% and 24%, respectively), increased apoptosis and induced mitochondrial depolarization. d4T, ZDV and ddC decreased adipocyte mtDNA (by 64%, 53% and 46%, respectively) and reduced the mtDNA encoded COX II subunit. Uridine (200 μM) had no intrinsic effect, but prevented all adverse effects of d4T, ZDV and ddC on adipocyte morphology, lipid staining, apoptosis, mtDNA depletion (partial prevention with ZDV), mitochondrial mass and membrane potential. The effects of uridine were concentration-dependent. Uridine also fully reverted established d4T toxicities despite continued d4T exposure.
Conclusions
Uridine supplementation protects adipocytes from the adverse effects of d4T, ZDV and ddC on lipid accumulation, cell survival and mitochondrial functions, suggesting that the toxic effects could be linked to intracellular depletion of uridine or its metabolites. Uridine is an interesting candidate in the prevention of NRTI-induced lipoatrophy in vivo.
References
1.
JolyV., FlandreP., MeiffredyV.Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial.AIDS2002; 16: 2447–2454.
2.
AminJ., MooreA., CarrA.Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: OzCombo 1 and 2.HIV Clin Trials2003; 4: 252–261.
3.
CheneG., AngeliniE., CotteL.Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients.Clin Infect Dis2002; 34: 649–657.
4.
DubeM.P., ParkerR.A., TebasP.Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides.AIDS2005; 19: 1807–1818.
5.
NolanD., MallalS.Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanisms.Antivir Ther2004; 9: 849–863.
6.
BrinkmanK., SmeitinkJ.A., RomijnJ.A., ReissP.Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy.Lancet1999; 354: 1112–1115.
7.
MartinJ.L., BrownC.E., Matthews-DavisN., ReardonJ.E.Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis.Antimicrob Agents Chemother1994; 38: 2743–2749.
8.
LewisW., DayB.J., CopelandW.C.Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective.Nat Rev Drug Discov2003; 2: 812–822.
9.
WalkerU.A., SetzerB., VenhoffN.Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors.AIDS2002; 16: 2165–2173.
10.
KakudaT.N.Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity.Clin Ther2000; 22: 685–708.
11.
McKeeE.E., BentleyA.T., HatchM., GingerichJ., Susan-ResigaD.Phosphorylation of thymidine and AZT in heart mitochondria: elucidation of a novel mechanism of AZT cardiotoxicity.Cardiovasc Toxicol2004; 4: 155–167.
12.
BecherF., PruvostA.G., SchlemmerD.D.Significant levels of intracellular stavudine triphosphate are found in HIV-infected zidovudine-treated patients.AIDS2003; 17: 555–561.
13.
BonoraS., BoffitoM., D'AvolioA.Detection of stavudine concentrations in plasma of HIV-infected patients taking zidovudine.AIDS2004; 18: 577–578.
14.
ArnaudoE., DalakasM., ShanskeS., MoraesC.T., DiMauroS., SchonE.A.Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy.Lancet1991; 337: 508–510.
15.
ChariotP., DrogouI., de Lacroix-SzmaniaI.Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion.J Hepatol1999; 30: 156–160.
16.
GerschensonM., PoirierM.C.Fetal patas monkeys sustain mitochondrial toxicity as a result of in utero zidovudine exposure.Ann N Y Acad Sci2000; 918: 269–281.
17.
ShiramizuB., ShikumaK.M., KamemotoL.Placenta and cord blood mitochondrial DNA toxicity in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy.J AIDS2003; 32: 370–374.
18.
WalkerU.A., VenhoffN., KochE.Uridine abrogates mitochondrial toxicity related to nucleoside analogue reverse transcriptase inhibitors in HepG2 cells.Antivir Ther2003; 8: 463–470.
19.
WalkerU.A., VenhoffN.Uridine in the prevention and treatment of NRTI-related mitochondrial toxicity.Antivir Ther2005; 10: M117–M123.
20.
CaronM., AuclairM., LagathuC.The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro.AIDS2004; 18: 2127–2136.
21.
LagathuC., BastardJ.P., AuclairM.Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro.Antivir Ther2004; 9: 911–920.
LaskinO.L., de MirandaP., BlumM.R.Azidothymidine steady-state pharmacokinetics in patients with AIDS and AIDS-related complex.J Infect Dis1989; 159: 745–747.
24.
DudleyM.N., GrahamK.K., KaulS.Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex.J Infect Dis1992; 166: 480–485.
25.
BurgerD.M., MeenhorstP.L., BeijnenJ.H.Concise overview of the clinical pharmacokinetics of dideoxynucleoside anti-retroviral agents.Pharm World Sci1995; 17: 25–30.
26.
GustavsonL.E., FukudaE.K., RubioF.A., DuntonA.W.A pilot study of the bioavailability and pharmacokinetics of 2′,3′-dideoxycytidine in patients with AIDS or AIDS-related complex.Journal of AIDS1990; 3: 28–31.
27.
SmileyS.T., ReersM., Mottola-HartshornC.Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1.Proc Natl Acad Sci USA1991; 88: 3671–3675.
HammondE.L., SayerD., NolanD.Assessment of precision and concordance of quantitative mitochondrial DNA assays: a collaborative international quality assurance study.J Clin Virol2003; 27: 97–110.
30.
HerrmannP.C., GillespieJ.W., CharboneauL.Mitochondrial proteome: altered cytochrome c oxidase subunit levels in prostate cancer.Proteomics2003; 3: 1801–1810.
31.
WalkerU.A., BäuerleJ., LagunoM.Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine.Hepatology2004; 39: 311–317.
32.
Saint-MarcT., PartisaniM., Poizot-MartinI.Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study.AIDS2000; 14: 37–49.
33.
BodnarA.G., CooperJ.M., HoltI.J., LeonardJ.V., SchapiraA.H.Nuclear complementation restores mtDNA levels in cultured cells from a patient with mtDNA depletion.Am J Hum Genet1993; 53: 663–669.
34.
KingM.P., AttardiG.Isolation of human cell lines lacking mitochondrial DNA.Meth Enzymol1996; 264: 304–313.
35.
LöfflerM., JöckelJ., SchusterG., BeckerC.Dihydroorotatubiquinone oxidoreductase links mitochondria in the biosynthesis of pyrimidine nucleotides.Mol Cell Biochem1997; 174: 125–129.
36.
FoxR.I.Mechanism of action of leflunomide in rheumatoid arthritis.J Rheumatol1998; 53(Suppl.): 20–26.
37.
OrenM.Regulation of the p53 tumor suppressor protein.J Biol Chem1999; 274: 36031–36034.
38.
SchulerM., GreenD.R.Mechanisms of p53-dependent apoptosis.Biochem Soc Trans2001; 29: 684–688.
39.
McComseyG.A., PaulsenD.M., LonerganJ.T.Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine.AIDS2005; 19: 15–23.
SaadaA., ShaagA., MandelH., NevoY., ErikssonS., ElpelegO.Mutant mitochondrial thymidine kinase in mitochondrial DNA depletion myopathy.Nat Genet2001; 29: 342–344.
42.
SommadossiJ.P., CarlisleR., SchinaziR.F., ZhouZ.Uridine reverses the toxicity of 3′-azido-3′-deoxythymidine in normal human granulocyte-macrophage progenitor cells in vitro without impairment of antiretroviral activity.Antimicrob Agents Chemother1988; 32: 997–1001.
43.
VenhoffN., ZillyM., LebrechtD.Uridine pharmacokinetics of Mitocnol, a sugar cane extract.AIDS2005; 19: 739–740.
44.
WalkerU.A., LangmannP., MiehleN., ZillyM., KlinkerH., PetschnerF.Beneficial effects of oral uridine in mitochondrial toxicity.AIDS2004; 18: 1085–1086.
